UKB is part of the Rheinische Friedrich-Wilhelms-Universität Bonn, a renowned research centre that is receiving funding within the Excellence Initiative of the German federal and state governments. The University Hospital Bonn (UKB) offers patient care including high-performance medicine and warrants the link between health care, research and education at the medical faculty. Prof. Lukas Radbruch is director of the Department of Palliative Medicine and holds the Chair in palliative medicine established in 2010.
In collaboration with the Centre for Palliative Medicine at the Malteser Hospital Bonn/Rhein-Sieg, the department offers inpatient care, a hospital support team and outpatient clinics and cooperates with the regional palliative home care network. The department organises medical student education as well as multi-professional education for nurses and physicians and psychosocial staff in palliative care and symptom management.
Current research projects include the identification of outcome factors for palliative care patients and a needs assessment survey on information needs in palliative care in Central and Eastern Europe and the Commonwealth of Independent States.
Role in the project
Bonn is the coordinator of the ATOME project and provides project management, communication within the consortium and coordination of the work packages. Moreover Bonn contributes with its scientific expertise to the project; this includes development of tools and mechanisms for regular monitoring and evaluation of progress in the different work packages. As part of the Project Management Team, Bonn will also coordinate the publication of reports, scientific papers and other material from the project in close collaboration with the work package leaders. Together with the International Observatory for end of Life Care, Lancaster University (ULANC), Bonn will have an overall responsibility for scientific aspects and liaise with the Academic Advisory Board.
The Eurasian Harm Reduction Network (EHRN) is a regional network with a mission to promote humane, evidence-based harm reduction approaches to drug use, with the aim of improving health and protecting human rights at the individual, community, and societal level. Founded in 1997, it is managed through regionally-elected representatives in its Steering Committee. Executive work is done through the Secretariat, established in 2001 and based in Vilnius, Lithuania. Its major activities and programs are research and information, policy and advocacy and technical support.
Role in the project
EHRN has the task to organise two important workshops in the course of the ATOME project: a six-country workshop in Bucharest (Romania) and a workshop for the review of recommendations in the follow up of legal assessment in Amsterdam (The Netherlands). Moreover, EHRN assists in the performance of other work packages with their specific expertise in the field of harm reduction, for example by helping to identify national partners for the country teams and by providing expertise to the revision of the WHO Guidelines Achieving Balance in National Opioids Control Policy.
The World Health Organization (WHO) is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. It was established in 1948 and is governed by 193 Member States through the World Health Assembly. Both WHO Headquarters and the WHO Regional Office for Europe are represented in the ATOME project.
The WHO Access to Controlled Medications Programme (ACMP) is located at WHO Headquarters in Geneva, Switzerland in the Department of Essential Medicines and Pharmaceutical Policies. It was established in February 2007 to promote the accessibility of medicines controlled under the international drug conventions.
The WHO Regional Office for Europe (WHO EURO) is situated in Copenhagen (Denmark) and serves a region made up of 53 countries, with over 880 million people that stretch from the Atlantic to the Pacific. The Regional Office's mission is to support WHO Member States in developing and sustaining their own health policies, health systems and public health programmes, working to prevent and overcome threats to health, anticipating future challenges, and advocating public health, with the common goal to ensure that the Region's citizens enjoy better health.
Role in the project
The WHO Access to Controlled Medications Programme provides the Consortium with the WHO policy guidelines Ensuring Balance in National Policies on Controlled Substances, Guidance for Accessibility and Availability of Controlled Medicines, which is an update of an older guideline. The ACMP contributes to the programme with its highly specialised and detailed knowledge on the situation with regard to this topic in many other work packages.
WHO EURO identifies the national counterparts responsible on the operational level for controlled substances legislation in the national governments of the countries that ATOME focuses on. WHO EURO contacts the relevant ministries and other relevant partners and provides the national counterparts with background information on the project.
Hospice Casa Sperantei (HCS) was the first organisation to pioneer palliative care in Romania starting in 1992, first in Brasov with the opening of a home care service; an education centre was added in 1997 and an out-patient clinic and in-patient unit with day centres for children and for adults were opened in 2002. In 2005 the hospice opened a branch in Bucharest providing home care for adults and children, mobile hospital teams in 2 major teaching hospitals and an education and resource centre;and in 2008, an out-patient clinic was opened. HCS has a leading role in developing national palliative care by closely working with government and authorities for changing legislation to accommodate this new type of services. HCS is leading the national diploma training program for palliative care in Romania and was recognised as one of the 5 centres of excellence in Eastern and Central Europe.
Role in the project
HCH will organize a two important workshops throughout the project: a workshop for the training of lawyers for legislation review in Bucharest (Romania) and a six-country workshop in Bucharest, Romania. Moreover, HCS will contribute to the scientific work and the dissemination of the ATOME project with their experience in national policy development, outstanding expertise in the area of palliative care advocacy, as well as their contacts on a national and international level.
Help the Hospices is the leading charity supporting hospice care throughout the UK. The majority of hospice care in the UK is provided by their member hospices. They represent and support their members and other organisations as they strive to grow and improve hospice and palliative care throughout the UK and across the world. Help the Hospices also has an international programme that supports the development of hospice and palliative care worldwide. They work with partners to provide a global voice on international hospice and palliative care issues. They provide resources to develop the capacity of hospice and palliative care services at national and local levels. Help the Hospices co-chairs the Worldwide Palliative Care Alliance (WPCA) which is a global action network that promotes universal access to affordable quality palliative care through the support of regional and national hospice and palliative care organisations.
For World Hospice and Palliative Care Day in 2007, Help the Hospices produced a report 'Access to pain relief - an essential human right' which addresses opioid access across the world.
Role in the project
Help the Hospices will organise national conferences in each of the twelve ATOME target countries. The aim of each conference is to communicate the results of the national analysis of barriers to opioid availability undertaken by the country teams.
Each conference will involve relevant national health-care professional associations, national "champions" and educational institutions. Through a mix of presentations by external speakers, group activities and exercises, the conferences will provide an intensive opportunity to discuss opioid accessibility, availability and affordability in each country. Recommendations will be made on the use of opioids for palliative care and substitution therapy and will encourage supportive national policies and plans.
Help the Hospices will provide the conference management, communication and coordination for the conferences.
Formerly known as the International Harm Reduction Association, the HRI is one of the leading international non governmental organisation promoting a harm reduction approach to psychoactive substances. Headquartered in London, HRI works to reduce drug related harms by promoting evidence based public health policy and practices and human rights based approaches to drug policy through an integrated programme of research, analysis, advocacy and collaboration with civil society partners. HRI's vision is a world in which individuals and communities benefit from drug laws, policies and practices that promote health, dignity and human rights.
Role in the project
Harm Reduction International has the task to coordinate national conferences in the ATOME target countries as follow-up to the national analyses undertaken by the country-teams in collaboration with Help the Hospices. The aim of these conferences is to communicate the results of the national analysis of barriers to opioid availability. Each of these events will have around 40 - 60 participants and will aim to enable information sharing, knowledge exchange and networking between international, regional and national substitution treatment experts and advocates, and relevant national health-care professional associations, government officials and policy makers, health-care professionals and main educational institution.
The Division of Pharmacoepidemiology and Clinical Pharmacology is one of four divisions of the Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, The Netherlands. In March 2008, the Division was designated as a WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy Analysis. By establishing this Centre, the Division aimed to create innovative synergies between the methods and contents of pharmaceutical policy analysis and pharmaco-epidemiology. The research programme is directed at several epidemiological, regulatory, policy, therapeutic and pharmacogenetic/genomic aspects of chronic drug use. The Division has established the only chair of pharmaceutical law in the Netherlands and it is in this environment that pharmaceutical law is taught and practiced.
Link to the WHO Collaboration Centre: www.pharmaceuticalpolicy.nl
Role in the project
Utrecht University will be responsible for the legislation analysis in the countries that are focused upon within the ATOME project. This task will include the evaluation of national legislation interacting with the accessibility and availability of controlled substances and the drafting, together with national counterparts, of recommendations (of a legal nature) for member states on improvement. Moreover, Utrecht University will contribute to several other work packages with their expertise and specific knowledge in the area of pharmaceutical policy and pharmaceutical law.
The International Observatory on End of Life Care (IOELC) was founded at Lancaster University (ULANC) in 2003 as the first ever research and development project to concentrate on the comparative analysis of hospice and palliative care around the world. Its aim is to add academic effort to the task of promoting the development of palliative care - locally, nationally and globally. It engages in projects and activities that have academic merit but which are also concerned with policy and service development and which can inform changes in clinical practice. Observatory staff characterise their approach as that of a 'critical friend' - supportive of the overall effort to improve palliative care while adding the distance and objectivity that comes with an academic orientation.
Role in the project
The IOELC will contribute to various work packages within the project with their scientific expertise and their technical competence. They have the responsibility to develop and maintain a project website incorporating an International Opioid Consumption Database. They will also provide evaluation tools and reports of workshops and conferences within the ATOME project. Together with UK Aachen, the IOELC has an overall responsibility for scientific aspects and liaises with the Academic Advisory Board. As a member of the Project Management Team, they will also take part in decision-making with regard to general project management and coordination.
The European Association for Palliative Care, Onlus (EAPC) was established in 1988, with the aim to promote palliative care in Europe and to act as a focus for all of those who work, or have an interest, in the field of palliative care at the scientific, clinical and social levels. It strives to develop and promote palliative care in Europe through information, education and research using multi-professional collaboration, while engaging with stakeholders at all levels. In 1998 the EAPC was awarded the status of NGO - Non Governmental Organisation of the Council of Europe, and was transformed to "Onlus" (Non profit organisation with social utility).In 2010, the EAPC counted individual members in 40 countries, with collective members from 47 National associations in 26 European countries. Within the EAPC is working a range of task forces on Ethics, on Education in palliative care of all health professionals, the care of specific patient groups such as children, older people or patients with neurological disease to set up white papers, recommendations, standards, curricula and the state of the art of Palliative care in Europe (Task Force for the Development of Palliative Care in Europe). Every second year EAPC organises a main congress for all the stakeholders to attend for update and every other year its Research Network organises a Congress focusing on Research in Palliative Care. EAPC is also very active in the promotion of palliative care at the European Institutions, present at the Council of Europe and coordinates actions towards governments.
Role in the project
EAPC has the task to support Bonn with the general project management, communication with project partners and coordination of the work packages. EAPC will facilitate dissemination and implementation of the guidelines and the results of the workshops and conferences via its website and its congresses. EAPC also provides scientific expertise to the project in general. Through its network of national associations, the EAPC brings in the flexible and free of cost translation services possibilities, for the translation of reports, scientific papers and other materials from the project that need a wide diffusion and will be published online. Through its mailing list the EAPC can diffuse the information to about 7000 healthcare professionals and volunteers in palliative care in Europe.
The National Anti-drug Agency, located within the Ministry of Administration and Interior, has been appointed by the Romanian Government to act as drug coordination unit in Romania. The Agency is involved in the formulation of the national drug strategy, the subsequent action plans, while also monitoring and coordinating the implementation of all drug-related activities included in the main policy documents related to drugs or other fields of national interest (public health, national security, safety and public order, etc). Additionally, the Agency ensures representation at European and international level and participation in the decision-making process at drug policy level. According to the European and national action lines, the features of the drug phenomenon and the local needs, the Agency coordinates, in a balanced manner, both drug demand and drug supply reduction measures at national level.
Additionally, through its 47 territorial Drug Prevention, Evaluation and Counseling Centers and the 5 fully operational Integrated Addiction Care Centers, the Agency, as service provider, tackles drug use and drug addiction in an integrated and multi-disciplinary manner, through specific psychological, medical and social interventions, based on the principle of case management.
Role in the project
The National Anti-drug Agency is involved in the ATOME project in work packages 3, 4 and 6 together with Hospice Casa Speran?ei and the Eurasian Harm Reduction Network.
The role of the NAA as ATOME consortium member:
- to host and to organise meetings and events with the representatives of the ATOME consortium
- to ensure participation of national state and NGO representatives involved in drug addiction treatment and the development of drug addiction services in Romania
- to ensure visibility of the ATOME project and its outputs at central and national level
- to ensure connection with all relevant organizations interested in the ATOME project.